Indexed in Journament

alimentary pharmacology & therapeutics

ISSN 1365-2036· EN

Certificate of Indexing
Login or register to claim ownership or editorship of this journal.
40.8 / 100
Journament Score
Below Average
Ranked #8,893 of 33,995 indexed journals
10 Articles
Accessibility 15
Engagement 31
The Journament Score combines content quality, publication ethics and transparency, editorial standards, publication regularity, accessibility and reader engagement into a single 0–100 figure. It is recalculated as new articles and metadata are indexed.

About This Journal

Short Name aliment pharmacol ther
Abbreviated Name aliment pharmacol ther
ISSN 1365-2036

Publications Per Year

Articles (10)

2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
Feagan BG;Sandborn WJ;Baker JP;Cominelli F;Sutherland LR;Elson CO;Salzberg BA;Archambault A;Bernstein CN;Lichtenstein GR;Heath PK;Cameron S;Hanauer SB;;
Vol. 21 , No. 4 , pp. -
450 views Abstract
2005
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens
Koivisto TT;Rautelin HI;Voutilainen ME;Heikkinen MT;Koskenpato JP;Färkkilä MA;;
Vol. 21 , No. 6 , pp. -
433 views Abstract
2007
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori
Fischbach L;Evans EL;;
Vol. 26 , No. 3 , pp. -
424 views Abstract
2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
Kiss LS;Szamosi T;Molnar T;Miheller P;Lakatos L;Vincze A;Palatka K;Barta Z;Gasztonyi B;Salamon A;Horvath G;Tóth GT;Farkas K;Banai J;Tulassay Z;Nagy F;Szenes M;Veres G;Lovasz BD;Vegh Z;Golovics PA;Szathmari M;Papp M;Lakatos PL; ;;
Vol. 34 , No. 8 , pp. -
377 views Abstract
2008
Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children
Ruszczyński M;Radzikowski A;Szajewska H;;
Vol. 28 , No. 1 , pp. -
330 views Abstract
2020
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk
Prizment AE;Staley C;Onyeaghala GC;Vivek S;Thyagarajan B;Straka RJ;Demmer RT;Knights D;Meyer KA;Shaukat A;Sadowsky MJ;Church TR;;
, pp. -
315 views Abstract
2005
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial
Kotowska M;Albrecht P;Szajewska H;;
Vol. 21 , No. 5 , pp. -
308 views Abstract
2020
Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply.
Tuck, Caroline;Vanner, Stephen;Camilleri, Michael;Jing Wang, Xiao;
Vol. 51 , No. 1 , pp. 185-186
291 views DOI
2019
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.
Gawrieh, Samer;Dakhoul, Lara;Miller, Ethan;Scanga, Andrew;deLemos, Andrew;Kettler, Carla;Burney, Heather;Liu, Hao;Abu-Sbeih, Hamzah;Chalasani, Naga;Wattacheril, Julia;
270 views DOI Abstract
2020
Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome.
Rej, Anupam;Buckle, Rachel Louise;Shaw, Christian Charles;Trott, Nick;Aziz, Imran;Surendran Sanders, David;
Vol. 51 , No. 1 , pp. 184-185
269 views DOI
2020
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk
Prizment AE;Staley C;Onyeaghala GC;Vivek S;Thyagarajan B;Straka RJ;Demmer RT;Knights D;Meyer KA;Shaukat A;Sadowsky MJ;Church TR;;
, pp. -
315 views Abstract
2020
Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply.
Tuck, Caroline;Vanner, Stephen;Camilleri, Michael;Jing Wang, Xiao;
Vol. 51 , No. 1 , pp. 185-186
291 views DOI
2020
Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome.
Rej, Anupam;Buckle, Rachel Louise;Shaw, Christian Charles;Trott, Nick;Aziz, Imran;Surendran Sanders, David;
Vol. 51 , No. 1 , pp. 184-185
269 views DOI
2019
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.
Gawrieh, Samer;Dakhoul, Lara;Miller, Ethan;Scanga, Andrew;deLemos, Andrew;Kettler, Carla;Burney, Heather;Liu, Hao;Abu-Sbeih, Hamzah;Chalasani, Naga;Wattacheril, Julia;
270 views DOI Abstract
2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
Kiss LS;Szamosi T;Molnar T;Miheller P;Lakatos L;Vincze A;Palatka K;Barta Z;Gasztonyi B;Salamon A;Horvath G;Tóth GT;Farkas K;Banai J;Tulassay Z;Nagy F;Szenes M;Veres G;Lovasz BD;Vegh Z;Golovics PA;Szathmari M;Papp M;Lakatos PL; ;;
Vol. 34 , No. 8 , pp. -
377 views Abstract
2008
Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children
Ruszczyński M;Radzikowski A;Szajewska H;;
Vol. 28 , No. 1 , pp. -
330 views Abstract
2007
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori
Fischbach L;Evans EL;;
Vol. 26 , No. 3 , pp. -
424 views Abstract
2005
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial
Kotowska M;Albrecht P;Szajewska H;;
Vol. 21 , No. 5 , pp. -
308 views Abstract
2005
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
Feagan BG;Sandborn WJ;Baker JP;Cominelli F;Sutherland LR;Elson CO;Salzberg BA;Archambault A;Bernstein CN;Lichtenstein GR;Heath PK;Cameron S;Hanauer SB;;
Vol. 21 , No. 4 , pp. -
450 views Abstract
2005
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens
Koivisto TT;Rautelin HI;Voutilainen ME;Heikkinen MT;Koskenpato JP;Färkkilä MA;;
Vol. 21 , No. 6 , pp. -
433 views Abstract
Journament Score
40.8/100 · Below Average
Ranked #8,893 of 33,995
Journament

Overall Quality Score

40.8/100

Tier: Below Average

The Journament Overall Quality Score is a comprehensive metric that evaluates academic journals across multiple dimensions including engagement, accessibility, diversity, innovation, and community impact.

This score helps researchers, institutions, and publishers understand the holistic quality and impact of a journal beyond traditional metrics.

Engagement Score

30.9/100

Measures user interactions, views, citations, and community involvement with this journal's content.

Higher engagement scores indicate that the journal's content is actively being read, cited, and discussed within the academic community.

Accessibility Score

15.0/100

Evaluates how easily researchers can access journal content, including open access availability, ISSN registration, and indexing.

This metric considers factors such as paywalls, open access policies, and availability across different academic databases and search engines.

Diversity Score

30.0/100

Assesses geographic and institutional diversity of authors, editorial board composition, and topic breadth.

A diverse journal publishes work from various geographic regions, institutions, and covers a broad range of topics within its field.

Innovation Score

40.0/100

Evaluates research novelty, interdisciplinary work, and emerging topics based on AI analysis of article abstracts.

This score reflects how much the journal publishes cutting-edge research, explores new methodologies, and bridges different academic disciplines.

Community Impact Score

34.0/100

Measures scholarly contribution and real-world applications of published research.

This metric evaluates how the journal's research translates into practical applications, policy changes, and benefits to society beyond academia.

Timeliness Score

50.0/100

Evaluates recent publication activity, publication frequency, and currency of research topics.

Higher scores indicate consistent publishing schedules and timely coverage of current research trends.

Ethics & Transparency Score

0.0/100

Research Integrity (10% weight)

Assesses COPE standards compliance, ethical considerations in research, transparency in methodologies, and reproducibility practices.

This metric ensures the journal maintains high ethical standards and promotes transparent, trustworthy research.

Content Quality Score

0.0/100

Academic Rigor (20% weight) + Methodology Quality (12%)

Evaluates research methodology soundness, statistical rigor, theoretical framework strength, appropriateness of research methods, data quality, and clarity & readability.

This comprehensive metric ensures published research meets the highest academic standards.

Editorial Diversity Score

0.0/100

Author Diversity + Interdisciplinary Value (8%)

Measures geographic diversity of authors, institutional variety, editorial board composition, and cross-disciplinary connections.

Diverse editorial teams bring varied perspectives and reduce bias in academic publishing.

Publication Regularity Score

0.0/100

Assesses consistency of publication schedule, frequency stability, and predictable output patterns.

Regular publication schedules indicate reliable journal operations and consistent workflow management.

Geographic Reach Score

0.0/100

Evaluates international author representation, global readership distribution, and cross-border research collaboration.

Wide geographic reach indicates global impact and international recognition of the journal's research.